• BHQ Workflows for SERCA and Calcium Signaling

  2026-08-20

  Build reproducible calcium-store depletion, vascular smooth muscle, and hematopoietic stem cell assays with BHQ, a mechanistically focused SERCA perturbagen. This guide pairs practical concentration, timing, control, and troubleshooting strategies with the CaMKII–STAT3–CXCR4 findings reported in recent HSC research.

• TBXA2R–ERM Signaling Drives TNBC Metastasis

  2026-08-20

  Leguay and colleagues identify TBXA2R as a GPCR that activates ezrin, radixin, and moesin through Gαq/11, Gα12/13, Rho GTPases, and the kinases SLK and LOK. The study connects this signaling axis to triple-negative breast cancer cell motility, invasion, and metastatic colonization, providing a mechanistic framework for studying cytoskeletal control of metastasis.

• Propranolol Workflows for Translational Research

  2026-08-19

  Build reproducible Propranolol assays across cardiovascular regulation, tremor biology, emotional memory modulation, and metabolic signaling. This workflow-led guide combines solvent planning, paired functional readouts, and TMS-informed assay design to distinguish peripheral β-blockade from central circuit effects.

• Simvastatin: Membrane-State-Aware Research

  2026-08-19

  Simvastatin (Zocor) is more than an HMG-CoA reductase inhibitor: its lactone-to-acid conversion and membrane localization can shape experimental outcomes. This guide translates membrane-biophysics findings into practical assay design for lipid metabolism and hepatic cancer research.

• Pyridostigmine, α-Bungarotoxin, and Placental Necroptosis

  2026-08-18

  The reference study identifies placental necroptosis as a pharmacologically tractable component of preeclampsia-like pathology in reduced uterine perfusion pressure rats. By combining pyridostigmine treatment with α7 nicotinic acetylcholine receptor antagonism, necroptosis inhibition, human placental analysis, and hypoxic trophoblast experiments, it links non-neuronal cholinergic signaling to placental inflammation and vascular dysfunction.

• GS967: Cardiac Late Sodium Current Inhibitor

  2026-08-18

  GS967 enables targeted suppression of pathological late Na+ influx for in vitro cardiac electrophysiology, ventricular myocyte studies, and ex vivo arrhythmia models. Its potency, voltage-dependent activity, and limited use-dependence make it useful for separating late-current mechanisms from broader conduction effects.

• ω-Agatoxin IVA TFA: A Precision Cav2.1 Lens

  2026-08-17

  ω-Agatoxin IVA TFA is a selective Cav2.1 probe that connects channel biophysics with synaptic release, seizure biology, and neuroprotection research. This thought-leadership guide explains how to deploy omega-agatoxin IVA strategically, interpret subtype-dependent potency, and avoid overextending preclinical findings toward therapeutic conclusions.

• Verapamil in Hypoxia-Driven Inflammation

  2026-08-17

  A translational framework for using Verapamil ((±)-Verapamil) to interrogate duration-dependent hypoxia, ROS/TXNIP/NLRP3 signaling, and urothelial inflammation while preserving appropriate controls for calcium-channel and P-glycoprotein biology.

• CLCC1 and Herpesvirus Nuclear Egress

  2026-08-16

  A 2024 bioRxiv preprint identifies CLCC1 as an essential host factor for the membrane-fusion step of herpesvirus nuclear egress. The study connects CLCC1 loss with perinuclear capsid accumulation, reduced viral production, and defective nuclear pore complex insertion, suggesting a shared membrane-remodeling mechanism in infection and uninfected cells.

• YM 58483 (BTP2) SOCE Blocker Guide

  2026-08-15

  This scenario-driven guide explains how YM 58483 (BTP2), a store-operated Ca2+ entry (SOCE) blocker, can clarify calcium-dependent results in T-cell, viability, cytotoxicity, and fibrosis assays. It provides practical interpretation and handling guidance for SKU B7542, with links to product information and primary literature.

• Isradipine (Dynacirc): Calcium Channel Workflows

  2026-08-14

  Isradipine (Dynacirc) provides a practical L-type calcium channel control for neuronal calcium-imaging, electrophysiology, and vascular smooth muscle experiments. This guide connects reproducible compound handling with a key pharmacology lesson: channel blockers must be interpreted within the selectivity and assay context.

• Balsalazide Disodium in Colitis Research

  2026-08-14

  Balsalazide disodium is a colon-targeted 5-aminosalicylic acid prodrug used in inflammation research and inflammatory bowel disease models. Its azoreductase-dependent activation, radiolabeling benchmarks, aqueous solubility, and preclinical limitations support controlled immunology assay design rather than direct extrapolation from animal or clinical dosing.

• ML133 HCl: Kir2.1 Workflow for Vascular Research

  2026-08-13

  ML133 HCl is a selective potassium channel inhibitor for connecting Kir2.1 activity with pulmonary artery smooth muscle cell behavior, vascular remodeling, and signaling. This practical guide covers assay setup, pH-aware dosing, migration and proliferation workflows, comparative controls, and troubleshooting.

• Polygodial for TRPA1 Channel Activation Studies

  2026-08-13

  Polygodial enables time-resolved TRPA1 activation studies that connect acute calcium entry with downstream NFAT and epithelial cytokine responses. This workflow combines live-cell ion-channel measurements, orthogonal pathway controls, and practical DMSO handling for sensory biology and neurophysiology research.

• Verapamil Beyond Cardiology: Hypoxia and Inflammation

  2026-08-12

  Verapamil is best known as a calcium channel blocker, yet recent urothelial-cell research positions it as a useful pharmacological probe for hypoxia-driven ROS/TXNIP/NLRP3 signaling. This article translates that finding into a rigorous, limitation-aware workflow for translational researchers.

3720 records 10/248 page Previous Next First page 上5页 678910 下5页 Last page